Spots Global Cancer Trial Database for Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
Official Title: A Phase 1 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Solid Tumors
Study ID: NCT00712504
Study Description
Brief Summary: This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be tested in patients with advanced solid tumors, including non small cell lung cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pfizer Investigational Site, Birmingham, Alabama, United States
Pfizer Investigational Site, Birmingham, Alabama, United States
Pfizer Investigational Site, Birmingham, Alabama, United States
Pfizer Investigational Site, Nashville, Tennessee, United States
Pfizer Investigational Site, Madison, Wisconsin, United States
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
